Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.